Further information
Find our more about:
Publication
To find out more about our partnerships and our therapeutic strategies, please consult:
|
|
Research & Development
Partnerships, sourcing skills and discoveries
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Innovating through partnerships
Innovation is a main driver of our transformation into a diversified global healthcare leader focused on patient needs. This is why we seek breakthrough innovations wherever they are found, i.e., in universities, research centers, biotech companies, venture capital portfolios - and of course in all parts of the world. Breakthrough innovations cannot be successfully found and developed without continual networking. This means ongoing communication with outside groups through scientific, entrepreneurial and flexible networks. By sharing visions, resources and strategy, we are building trustful long-term partnerships to find pioneering solutions for unmet medical needs. Innovation, the core of sanofi-aventis’ strategy, starts with creativity, curiosity and open-mindedness. Science helps build knowledge and innovation, daily reminder that partnerships are a foundation for progress. Future successes in our industry will come from building on shared ideas. Team spirit has always been vital to medicine. From top management and throughout our organization we are committed to ensuring that external breakthrough discoveries become successful innovative products.
An accelerating deal flow
Sanofi-aventis is developing a partnership strategy, particularly in biotechnologies and biotherapy, forging strategic partnerships around the world with recognized experts to achieve faster, better progress towards new therapeutic solutions. In 2009, the implementation of this dynamic strategy to increase R&D innovation within and outside our walls resulted in the signature of 33 partnerships and acquisitions, including 18 R&D partnerships and licensing deals. This implementation is going at a fast pace, and the Group is planning to keep up the pace in 2010. As a global healthcare company, we are looking for all public and private partnerships that will open a door to new solutions for better health. We want to remain at the cutting edge in many fields, including biotherapy, stem cells and regenerative medicine or simply expand our portfolio with services or technologies that are not currently among our key areas of research. This will enable us not only to maintain our leadership in our current fields of therapeutic expertise, but also to seek out products and therapies in areas which our own programs have not yet explored. Demand for new and existing vaccines is estimated to double by year 2016. Sanofi Pasteur has developed partnership opportunities to boost its development and production of human vaccines for both prophylactic and therapeutic purposes. Current areas of sanofi pasteur vaccine development include vaccines to fight infectious diseases, cancer and chronic diseases.
Our main partners in biotechnology
Biotech Companies
-
Biotech Companies
Alopexx Pharmaceuticals
- Date of signature
-
December, 2009
- Location
-
Cambridge, Massachusetts, USA
- Nature of the partnership
-
Collaboration agreement with an option for a license
- Partnership objective
-
Development of a novel human monoclonal antibody targeting infectious diseases
- Information on Alopexx
-
CureDM, Wilmington, DE, USA
Biotech Companies
-
Biotech Companies
Dyax
- Date of signature
-
February, 2008
- Location
-
Cambridge, Massachusetts, USA
- Nature of the partnership
-
Exclusive license agreement for the development and commercialization of the fully human monoclonal antibody and worldwide non exclusive license to Dyax’s phage display technology
- Partnership objective
-
Development of the sanofi-aventis’ portfolio in biotherapeutics leveraging Dyax’s phage display technology to generate potential first/best-in-class antibody drug candidates
- Information on Dyax
-
-
Biotech Companies
Exelixis
- Date of signature
-
May, 2009
- Location
-
San Francisco, California, USA
- Nature of the partnership
-
Exclusive global license to XL147 (SAR245408) and XL765 (SAR245409) and Research and license agreement on isoform selective compounds
- Partnership objective
-
Develop novel targeted oncology therapies and obtain exclusive worldwide license for selective inhibitors of phosphoinositide-3-kinase (PI3K)
- Information on Exelixis
-
-
Biotech Companies
ImmunoGen
- Dates of signatures
-
- Location
-
Cambridge, Massachusetts, USA
- Nature of the partnership
-
- Research agreement (from 2003 to 2008)
- Collaboration and license agreement (from August 2008)
- Partnership objective
-
- To discover and develop naked monoclonal antibodies and immunoconjugates in oncology
- Non-exclusive license for the humanization of antibodies and for the generation of immunoconjugates
- Information on ImmunoGen
-
-
Biotech Companies
Merrimack Pharmaceuticals
- Date of signature
-
October, 2009
- Location
-
Cambridge, Massachusetts, USA
- Nature of the partnership
-
Exclusive worldwide license and collaboration to develop, manufacture and commercialize MM-121 (SAR256212)
- Partnership objective
-
Strengthen the sanofi-aventis oncology portfolio for solid malignancies with potential first in class targeted cancer therapies
- Information on Merrimack Pharmaceuticals
-
-
Biotech Companies
Micromet
- Date of signature
-
October, 2009
- Location
-
- Bethesda, MD, USA (Corporate Headquarters)
- Munich, Germany (R&D Center)
- Nature of the partnership
-
Global collaboration and license agreement
- Partnership objective
-
Development of a BITE® antibody against an antigen present at the surface of carcinoma cells. BITE® antibodies are novel therapy that activates patients’ T cells to seek out and destroy cancer cells
- Information on Micromet
-
-
Biotech Companies
Regeneron
- Dates of agreements:
-
- 3rd agreement: November, 2009 (amendment to antibody collaboration)
- 2nd agreement: November, 2007 (antibody collaboration)
- 1st agreement: September 2003 (license and collaboration agreement for Aflibercept)
- Location
-
Tarrytown, New York, USA
- Nature of the most recent agreement
-
Global strategic collaboration agreement to discover, develop, and commercialize fully-human therapeutic antibodies with exclusive option to co-develop each drug candidate in the collaboration portfolio.
- Partnerships objective
-
- Expand and extend initial antibody collaboration to discover, develop and commercialize fully-human monoclonal antibodies
- Development of fully-human therapeutic monoclonal antibodies utilizing the Regeneron’s antibody technologies (VelociSuite and next generation technologies)
- Development of aflibercept (VEGF-trap) - currently in Phase III
- Information on Regeneron
-
Syntiron, St Paul, MI, USA
Biotech Companies
-
Biotech Companies
Wellstat Therapeutics
- Date of signature
-
October, 2009
- Location
-
Gaithersburg, Maryland, USA
- Nature of the partnership
-
Exclusive worldwide license to develop, manufacture and commercialize PN2034 and related compounds
- Partnership objective
-
Strengthen the sanofi-aventis diabetes portfolio in which Lantus® has become the leading insulin
- Information on Wellstat Therapeutics
-
Academia / Consortium
-
Academia / Consortium
California Institute of Technology (Caltech)
- Date of signature
-
December, 2009
- Location
-
Pasadena, California, USA
- Nature of the partnership
-
Strategic research alliance
- Partnership objective
-
Complement sanofi-aventis research technologies supporting bioengineering for the development of therapeutic and diagnostic solutions
- Information on Caltech
-
-
Academia / Consortium
Johns Hopkins University
- Date of signature
-
July, 2008
- Location
-
Baltimore, Maryland, USA
- Nature of the partnership
-
Research agreement
- Partnership objective
-
Discover and develop novel ways to treat severe respiratory diseases and allergy, as well as improve the design of clinical studies
- Information on Johns Hopkins University
-
-
Academia / Consortium
Rockefeller University
- Date of signatures
-
2007 and November, 2009
- Location
-
New York, NY, USA
- Nature of the partnership
-
- Research collaboration agreement with the option to license a monoclonal antibody (mab) (from 2007 to Nov. 2009)
- Global licensing agreement for this mab (from Nov. 2009)
- Partnership objective
-
Enrich sanofi-aventis product pipeline with a monoclonal antibody that may have a significant positive impact in the management of patients with Alzheimer disease.
- Information on Rockefeller University
-
-
Academia / Consortium
Salk Institute for Biological Studies
- Date of signature
-
March, 2009
- Location
-
La Jolla, California, USA
- Nature of the partnership
-
Strategic research alliance
- Partnership objective
-
Enrich sanofi-aventis research projects in the field of regenerative medicine to apply discoveries to potential new diagnostics or therapies
- Information on Salk Institute
-
-
Academia / Consortium
University of Pennsylvania
- Date of signature
-
February 2008
- Location
-
Philadelphia, Pennsylvania, USA
- Nature of the partnership
-
Research agreement
- Partnership objective
-
Enrich sanofi-aventis research projects in the field of anti-Acute Myeloid Leukemia (AML) stem cell antibodies
- Information on University of Pennsylvania
-
Acquisition
-
Acquisition
BiPar Sciences
- Date of acquisition
-
April, 2009
- Location
-
Brisbane, California, USA
- Acquisition objective
-
Strengthen the sanofi-aventis oncology portfolio through a potential first in class/best in class PARP inhibitor treatment for Triple Negative Breast Cancer (TNBC), ovarian cancer and other malignancies
- Information on BiPar Sciences
-
Biotech Companies
Genfit, Lille, France
Biotech Companies
-
Biotech Companies
Novozymes
- Date of signature
-
December, 2008
- Location
-
Bagsvaerd, Denmark
- Nature of the partnership
-
Exclusive worldwide license and collaboration agreement
- Partnership objective
-
Strengthen the sanofi-aventis’ portfolio of anti-infectious compounds targeting the treatment of severe infections that cannot be properly managed with existing therapies
- Information on Novozymes
-
-
Biotech Companies
Oxford BioMedica
- Dates of agreements
-
- Date of 2nd agreement: April, 2009
- Date of 1st agreement: March, 2007
- Location
-
The Oxford Science Park, Oxford, UK
- Nature of the most recent partnership
-
Collaboration agreement to develop novel gene-base medicines with an exclusive option for worldwide license
- Objective of recent partnership
-
Strengthen sanofi-aventis portfolio with novel gene-based medicines for treatment of the growing field of back of the eye diseases
- Information on Oxford BioMedica
-
-
Biotech Companies
Zealand Pharma
- Date of signature
-
June 2003
- Location
-
Glostrup, Denmark
- Nature of the partnership
-
License agreement
- Partnership objective
-
Enhance sanofi-aventis’ diabetes product pipeline
- Information on Zealand Pharma
-
Academia / Consortium
AVIESAN (French Life Sciences and Healthcare Alliance)
Academia / Consortium
Innovative Medicines Initiative (European public-private partnership)
Academia / Consortium
Institut de la Vision, Paris, France
Academia / Consortium
Acquisition
-
Acquisition
Fovea Pharmaceuticals
- Date of acquisition
-
October, 2009
- Location
-
Paris, France
- Acquisition objective
-
Development of sanofi-aventis’ ophthalmology franchise leveraging Fovea’s platform to identify new protein factors and small molecular entities for ocular, in particular retinal diseases
- Information on Fovea
-
Biotech Companies
-
Biotech Companies
BioWa
- Date of signature
-
April, 2009
- Location
-
Princeton, New Jersey, USA
- Nature of the partnership
-
Non-exclusive license agreement providing access to BioWa’s POTELLIGENT Technology
- Partnership objective
-
Improve the effectiveness of sanofi-aventis antibody-based treatments across many therapeutic categories
- Information on BioWa
-
Huya, China
Biotech Companies
Kitasato Institute research center for biologicals, Japan
Biotech Companies
-
Biotech Companies
Kyowa Kirin
- Date of signature
-
May, 2009
- Location
-
Tokyo, Japan
- Nature of the partnership
-
Exclusive rights to develop the anti-LIGHT antibody
- Partnership objective
-
Strengthen sanofi-aventis pipeline in the field of inflammation
- Information on Kyowa Kirin
-
Academia / Consortium
-
Academia / Consortium
The Institute of Hematology and Blood Diseases Hospital
- Date of signature
-
September, 2007
- Location
-
Tianjin, China
- Nature of the partnership
-
Research agreement
- Partnership objective
-
Strengthen sanofi-aventis’ oncology portfolio in the area of liquid tumors and acute myeloid leukemia (AML). Isolation of AML stems cells and generation of monoclonal antibodies against these cells.
- Information on Institute of Hematology and Blood Diseases Hospital
-
Khotro/Khidi, South Korea
Academia / Consortium
-
Academia / Consortium
Shanghai Institutes for Biological Sciences (SIBS)
- Date of signature
-
October, 2008
- Location
-
Shanghai, China
- Nature of the partnership
-
Strategic research agreement
- Partnership objective
-
- Identify innovative, first-in-class drugs to strengthen sanofi-aventis portfolio in neurological diseases, diabetes and cancer both for biopharmaceutical agents as well as vaccines
- Strengthen the R&D presence of sanofi-aventis in China
- Information on SIBS
-
Acquisition
Shantha, Hyderabad, India
Acquisition
|
|
